August 6, 2019 – Inflammatix Wins AACC’s Disruptive Technology Award For Its Rapid HostDx™ Tests

By |2019-08-06T15:48:57-07:00August 6th, 2019|Categories: |

Burlingame, Calif., August 6, 2019  --- Inflammatix, a molecular diagnostics company that is reimagining diagnostics, announced today that it has received the American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis. The award was based on the company's presentation [...]

Comments Off on August 6, 2019 – Inflammatix Wins AACC’s Disruptive Technology Award For Its Rapid HostDx™ Tests

May 16, 2019 – Inflammatix Named a Finalist for AACC’s Disruptive Technology Award for Its Rapid HostDx™ Tests

By |2019-05-16T12:58:28-07:00May 16th, 2019|Categories: |

Burlingame, Calif., May 16, 2019  --- Inflammatix announced today that it has been named a finalist for the American Association for Clinical Chemistry’s (AACC) Disruptive Technology Award  for its rapid HostDx™ tests, which read the immune system to improve diagnosis of acute infections and sepsis. Inflammatix is one of three finalists that will present its technology at the 71st [...]

Comments Off on May 16, 2019 – Inflammatix Named a Finalist for AACC’s Disruptive Technology Award for Its Rapid HostDx™ Tests

October 4, 2018 – Inflammatix to Present New Data at IDWeek 2018 Demonstrating Ability to Perform HostDx™ Fever Test to Rapidly Distinguish Bacterial from Viral Infections Across Multiple Laboratory Platforms

By |2018-10-16T16:49:43-07:00October 4th, 2018|Categories: |

Burlingame, Calif., October 4, 2018  --- Inflammatix today announced that it will present findings from two studies demonstrating the ability of its HostDx™ Fever test to distinguish bacterial from viral infections on multiple rapid laboratory platforms that can deliver results in under 30 minutes. The new data will be presented at the Infectious Diseases Society of [...]

Comments Off on October 4, 2018 – Inflammatix to Present New Data at IDWeek 2018 Demonstrating Ability to Perform HostDx™ Fever Test to Rapidly Distinguish Bacterial from Viral Infections Across Multiple Laboratory Platforms

April 10, 2018 – Inflammatix Named a Finalist in Fast Company’s 2018 World Changing Ideas Awards for Its Novel HostDx Tests

By |2018-04-10T09:55:32-07:00April 9th, 2018|Categories: |

Burlingame, Calif., April 10, 2018  --- Inflammatix announced today that it has been named a finalist in Fast Company’s 2018 World Changing Ideas Awards for its novel HostDx™ tests, which read the immune system to tackle the global health problems of antibiotic resistance and sepsis. The annual award honors businesses, policies, projects and concepts that offer [...]

Comments Off on April 10, 2018 – Inflammatix Named a Finalist in Fast Company’s 2018 World Changing Ideas Awards for Its Novel HostDx Tests

February 15, 2018 – New Study Published in Nature Communications Suggests Sepsis Can Be Detected By Measuring the Immune System

By |2018-02-15T12:09:09-07:00February 15th, 2018|Categories: |

Bioinformatics Approach Forms the Basis of Inflammatix’s HostDx™ Sepsis Test Burlingame, Calif., February 15, 2018 --- Inflammatix announced findings from a new study published today in Nature Communications that suggest that diagnosing and determining who will likely develop sepsis can be improved with a data-driven approach that measures the immune system response to severe infection. [...]

Comments Off on February 15, 2018 – New Study Published in Nature Communications Suggests Sepsis Can Be Detected By Measuring the Immune System

December 19, 2017 – Inflammatix Announces Appointment of Oliver Liesenfeld, M.D., as Chief Medical Officer

By |2018-10-16T16:53:44-07:00December 19th, 2017|Categories: |

BURLINGAME, Calif., Dec. 19, 2017 /PRNewswire/ -- Inflammatix, a molecular diagnostics company that is developing rapid tests that read the immune system to improve disease diagnosis, today announced that Oliver Liesenfeld, M.D., has been appointed chief medical officer. Dr. Liesenfeld, a veteran of the diagnostics industry, comes to the company from Roche Molecular Diagnostics, where he served as chief [...]

Comments Off on December 19, 2017 – Inflammatix Announces Appointment of Oliver Liesenfeld, M.D., as Chief Medical Officer